<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322708</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-014</org_study_id>
    <nct_id>NCT04322708</nct_id>
  </id_info>
  <brief_title>A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis</brief_title>
  <acronym>KRYPTOS</acronym>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to&#xD;
      assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and&#xD;
      adolescent patients with active eosinophilic esophagitis. Subjects who complete the&#xD;
      randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses&#xD;
      of open-label lirentelimab (AK002) through the OLE Period of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who achieve esophageal intraepithelial eosinophil count of ≤6 eosinophils/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean absolute change in Dysphagia Symptom Questionnaire (DSQ) score</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in esophageal intraepithelial eosinophil count</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving esophageal intraepithelial eosinophil count of ≤1 eosinophil/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving esophageal intraepithelial eosinophil count of ≤15 eosinophil/hpf</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treatment responders when a responder is a patient achieving &gt;30% reduction in symptoms (DSQ) and achieving a peak intraepithelial eosinophilic count of ≤6 eosinophils/hpf</measure>
    <time_frame>At Weeks 23-24 and at Week 24, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &gt;50% reduction in DSQ score</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in DSQ score</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biweekly mean DSQ over time.</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in EoE Reference Score for Endoscopic Abnormalities (EREFS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lirentelimab (AK002)</intervention_name>
    <description>Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.</description>
    <arm_group_label>1 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>3 mg/kg of lirentelimab (AK002)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥12 and ≤80 years at the time of signing ICF.&#xD;
&#xD;
          2. Confirmed diagnosis of EoE and esophageal intraepithelial eosinophilic infiltration of&#xD;
             ≥15 eosinophils/hpf in 1 hpf from a biopsy collected during the Screening EGD without&#xD;
             any other cause for the esophageal eosinophilia.&#xD;
&#xD;
          3. History (by patient report) of an average of ≥2 episodes of dysphagia with intake of&#xD;
             solid foods per week during the 4 weeks prior to Screening.&#xD;
&#xD;
          4. Subjects must have failed or not be adequately controlled on standard of care&#xD;
             treatments for EoE symptoms, which could include PPI, systemic or topical&#xD;
             corticosteroids, and/or diet, among others.&#xD;
&#xD;
          5. If on an allowed treatment for EoE, stable dose for at least 4 weeks prior to&#xD;
             Screening and willingness to continue that dose for the study duration.&#xD;
&#xD;
          6. If patient is on pre-existing dietary restrictions, willingness to maintain dietary&#xD;
             restrictions throughout the study, as much as possible.&#xD;
&#xD;
          7. Able and willing to comply with all study procedures.&#xD;
&#xD;
          8. Female subjects must be either post-menopausal for at least 1 year with FSH level &gt;30&#xD;
             mIU/mL at Screening or surgically sterile (tubal ligation,hysterectomy, or bilateral&#xD;
             oophorectomy) for at least 3 months, or if of childbearing potential, have a negative&#xD;
             pregnancy test and agree to use dual methods of contraception, or abstain from sexual&#xD;
             activity from screening until the end of the study, or for 120 days following the last&#xD;
             dose of study drug, whichever is longer. Male subjects with female partners of&#xD;
             childbearing potential must agree to use a highly effective method of contraception&#xD;
             from Screening until the end of the study or for 120 days following the last dose of&#xD;
             study drug,whichever is longer. All fertile men with female partners of childbearing&#xD;
             potential should be instructed to contact the Investigator immediately if they suspect&#xD;
             their partner might be pregnant at any time during study participation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Concomitant EG, EoD, or eosinophilic colitis (EC).&#xD;
&#xD;
          2. EG and/or EoD (≥30 eosinophils/hpf in 5 hpf in the stomach and/or ≥30 eosinophils/hpf&#xD;
             in 3 hpf in the duodenum) as determined by central histology assessment of biopsies&#xD;
             collected during the Screening EGD.&#xD;
&#xD;
          3. Causes of esophageal eosinophilia other than EoE or one the following:&#xD;
             hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, or&#xD;
             peripheral blood absolute eosinophil count of &gt;1500 eosinophils/μL.&#xD;
&#xD;
          4. History of inflammatory bowel disease, celiac disease, achalasia, and/or esophageal&#xD;
             surgery.&#xD;
&#xD;
          5. Any esophageal stricture unable to be passed with a standard diagnostic 9 mm to 10 mm&#xD;
             upper endoscope or any critical esophageal stricture that requires dilation during&#xD;
             screening.&#xD;
&#xD;
          6. History of bleeding disorders or esophageal varices.&#xD;
&#xD;
          7. History of malignancy; except carcinoma in situ, early stage prostate cancer, or&#xD;
             non-melanoma skin cancers. However, cancers that have been in remission for more than&#xD;
             5 years and are considered cured, can be enrolled (with the exception of breast&#xD;
             cancer). All history of malignancy (including diagnosis, dates, and compliance with&#xD;
             cancer screening recommendations) must be documented and certified by the&#xD;
             Investigator, along with the statement that in their clinical judgment the tissue&#xD;
             eosinophilia is attributable to EGID, rather than recurrence of malignancy.&#xD;
&#xD;
          8. Active Helicobacter pylori infection (as determined by central histology staining of&#xD;
             the biopsy collected during the Screening EGD), unless treated and confirmed to be&#xD;
             negative prior to randomization and symptoms remain consistent.&#xD;
&#xD;
          9. Positive Ova and Parasite (O&amp;P) test at Screening, seropositive for Strongyloides&#xD;
             stercoralis at Screening, and/or treatment for a clinically significant helminthic&#xD;
             parasitic infection within 6 months of Screening.&#xD;
&#xD;
         10. Seropositive for HIV or hepatitis at Screening, except for vaccinated patients or&#xD;
             patients with a history of hepatitis that has since resolved.&#xD;
&#xD;
         11. Prior exposure to AK002 or hypersensitivity to any constituent of AK002.&#xD;
&#xD;
         12. Change in dose of inhaled corticosteroids, nasal corticosteroids, PPI, and/or diet&#xD;
             therapy within 4 weeks prior to Screening.&#xD;
&#xD;
         13. Use of oral corticosteroids (swallowed topical or systemic corticosteroids) within 8&#xD;
             weeks prior to Screening.&#xD;
&#xD;
         14. Use of any biologics or medications that may interfere with the study, such as&#xD;
             immunosuppressive or immunomodulatory drugs including azathioprine, JAK inhibitors,&#xD;
             6-mercaptopurine, methotrexate, cyclosporine, tacrolimus, anti-TNF, anti-IL-4&#xD;
             receptor, e.g., dupilumab), anti-IL-5 (e.g., mepolizumab), anti-IL-5 receptor (e.g.,&#xD;
             benralizumab), anti-IL-13 (e.g., lebrikizumab), anti-IgE (e.g., omalizumab), within 12&#xD;
             weeks prior to Screening.&#xD;
&#xD;
         15. Participation in a concurrent interventional study with the last intervention&#xD;
             occurring within 30 days prior to administration of study drug or 90 days or 5&#xD;
             half-lives, whichever is longer, for biologic products.&#xD;
&#xD;
         16. Vaccination with live attenuated vaccines ≤30 days prior to initiation of treatment in&#xD;
             the study, during the treatment period, or vaccination expected ≤5 half-lives (≤4&#xD;
             months) following study drug administration.&#xD;
&#xD;
         17. Treatment with chemotherapy or radiotherapy in the preceding 6 months.&#xD;
&#xD;
         18. Presence of abnormal laboratory values considered by the Investigator to be clinically&#xD;
             significant.&#xD;
&#xD;
         19. Any disease, condition (medical or surgical), or cardiac abnormality, which in the&#xD;
             opinion of the Investigator, would place the subject at increased risk.&#xD;
&#xD;
         20. Known history of alcohol, drug, or other substance abuse or dependence.&#xD;
&#xD;
         21. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
         22. Any other reason that in the opinion of the Investigator or Medical Monitor makes the&#xD;
             patient unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Paterson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EoE</keyword>
  <keyword>Eosinophil</keyword>
  <keyword>Esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

